Topiramate Tablet
Product Images NDC 69097-122

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 69097-122). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cipla Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 01

FDA Label Image

Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 02

FDA Label Image

Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 03

This text appears to be a statistical report of a medical study on the effectiveness of Topamax for treating migraines. The study has a double-blind phase, and the text indicates a change from baseline in average monthly migraine period rate, which increased by 56. It also lists different dosages of Topamax, 100mg/day and 200mg/day. There are some statistical significance values listed as well, indicating that the results are significant.*

FDA Label Image

Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 04

This is a description of Topiramate tablets, USP, manufactured by Cipla Ltd., India, for Cipla USA, Inc. The tablets come in a container of 60 white, film-coated tablets, each containing 25 mg of Topiramate USP. The usual dosage information is included in the package insert. Pharmacists are instructed to dispense the enclosed medication guide to each patient and to store the tablets at a temperature of 20°C to 25°C, and protect from moisture. The label includes information such as the manufacturer's address, lot number, expiry date, and SAP code, among others.*

FDA Label Image

Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 05

This is a brief description of a prescription drug that contains Topiramate LSP at 50 mg per tablet. The tablets are manufactured by Cipla Ltd. in India and distributed in the US by Cipla USA. The pharmacist is instructed to dispense the tablets in a defined container, use child-resistant closure and protect from moisture. The label indicates that a medication guide should be provided to each patient. The rest of the text pertains to manufacturing details and is not relevant to the drug's description.*

FDA Label Image

Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 06

This is a description of a medication called Topiramate USP, with a dosage of 100mg. The medication is packaged in filtncoated tablets, with each tablet containing 100mg of Topiramate USP. The NDC number listed on the package is 63097-124-03. The medication is controlled and must be stored in a light-resistant container with a child-resistant closure. The tablets must be stored at a temperature of 20°-25°C. The medication is manufactured in India by Cipla Lic and is intended for distribution by Cipla USA, Inc. It comes in a package of 60 orange tablets. The label includes a batch overprinting area and a SAP code of 219424 (Ver. 01). Expiry and lot numbers will be overprinted during commercial packing. Dispensing instructions and a medication guide are included with the package.*

FDA Label Image

Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 07

This is a description of Exch, a film-coated tablet that contains 200 mg of Topiramate USP. It is manufactured by Gipla Ltd. and distributed by Cipla USA, Inc. The tablet is designed to be stored in a controlled room temperature environment, between 20°C to 25°C (68°F to 77°F), and protected from moisture. The packaging includes a medication guide for the patient. Additional details include the NDC (National Drug Code) number: 63097-12503 R only (535 dosage: So6 package eart), the pharmacist reference number 219427 Rev. 10/2020, a batch overprinting area, and a date of 4/11/2020.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.